19-protein MASLD score

There is 1 paper on 19-protein MASLD score in aging research: 1 observational study in people. The newest story, Oct 30, 2026: “Kidney disease linked to metabolic fatty liver disease both ways”.

Biomarker

1 paper studies it1 finding

1 new paper in 30 daysSee all 1

“The 37-protein CKD and 19-protein MASLD scores improved discrimination beyond clinical factors in internal testing and geographical validation within UK Biobank.”
Bidirectional associations and shared plasma proteomic signatures of CKD and MASLD: evidence from a population-based prospective cohort and a real-world hospital cohortNutrition, metabolism, and cardiovascular diseases : NMCD2026doi:10.1016/j.numecd.2026.105039
  • Humans1

Associations

1

Metabolic dysfunction-associated steatotic liver disease

upin humans1

1 study
  1. 19-protein MASLD score predicts metabolic dysfunction-associated steatotic liver disease in humans (internal testing and geographical validation within UK Biobank) (C-index 0.775 to 0.817 in internal testing).

    “The 37-protein CKD and 19-protein MASLD scores improved discrimination beyond clinical factors in internal testing and geographical validation within UK Biobank.”

    Humansinternal testing and geographical validation within UK Biobank

    Kidney disease linked to metabolic fatty liver disease both ways

    Nutrition, metabolism, and cardiovascular diseases : NMCD

More on Metabolic dysfunction-associated steatotic liver disease

Latest

Nov 2025: 0Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 11 paper in 12 months
Nutrition, Metabolism, and Cardiovascular Diseases

Kidney disease linked to metabolic fatty liver disease both ways

Chronic kidney disease was linked to later metabolic fatty liver disease (hazard ratio 1.36); the reverse link had a ratio of 1.64, versus people without each condition.Chronic kidney disease was linked to later metabolic fatty liver disease (hazard ratio 1.36); the reverse link had a ratio of 1.64, versus people without each condition.

Cohort · 462,516 peopleBiomarkers